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ABSTRACT
Prostate cancer can transform from androgen-responsive to an androgen-
independent phenotype. The mechanism responsible for the transformation remains 
unclear. We studied the effects of an epigenetic modulator, phenethyl isothiocyanate 
(PEITC), on the androgen-responsive LNCaP cells. After treatment with PEITC, floating 
spheres were formed with characteristics of prostate cancer stem cells (PCSC). These 
spheres were capable of self-renewal in media with and without androgen. They 
have been maintained in both types of media as long term cultures. Upon androgen 
deprivation, the adherent spheres differentiated to neuroendocrine cells (NEC) with 
decreased proliferation, expression of androgen receptor, and PSA. NEC reverse 
differentiated to spheres when androgen was replenished. The sphere cells expressed 
surface marker CD44 and had enhanced histone H3K4 acetylation, DNMT1 down-
regulation and GSTP1 activation. We hypothesize that PEITC-mediated alteration 
in epigenomics of LNCaP cells may give rise to sphere cells, whereas reversible 
androgenomic alterations govern the shuttling between sphere PCSC and progeny 
NEC. Our findings identify unrecognized properties of prostate cancer sphere cells with 
multi-potential plasticity. This system will facilitate development of novel therapeutic 
agents and allow further exploration into epigenomics and androgenomics governing 
the transformation to hormone refractory prostate cancer.
INTRODUCTION
Prostate cancer initially responds to androgen 
deprivation therapy but eventually becomes refractory to 
hormone therapy. These hormone refractory cancer cells 
grow independently of androgen, become highly aggressive, 
and metastasize quickly. Hormone refractory prostate 
cancer leads to high mortality since there lacks effective 
therapy. One major reason is that the precise molecular 
mechanisms responsible for the cancer progression remain 
unclear. The most prominent mechanisms postulated to 
date involve the androgen receptor (AR). They include AR 
gene mutation, excessive recruitment of AR transcription 
co-regulators [1, 2], non-AR-related bypass pathways [3], 
and epigenetic alterations including hypermethylation of 
AR promoter [4]. Other mechanisms postulated include 
the involvement of prostate cancer stem cells (PCSC). 
Epithelial androgen-independent prostate cancer stem cells 
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or AR negative stem cells have been hypothesized to be 
present in the prostate cancers which become enriched by 
androgen deprivation therapy [5, 6].
Prostate cancer stem cells have been a subject of 
our research. We reported in 1999 that the androgen-
dependent human prostate cancer cells LNCaP could be 
induced to form neuroendocrine cells by interleukin 1. 
These neuroendocrine cells were significantly attenuated 
in proliferation and in PSA production [7]. Similarly, Bang 
et al reported that LNCaP cells underwent neuroendocrine 
cell differentiation mediated by cyclic AMP analogues [8]. 
Clinical cases of transformation of prostate adeno carcinoma 
to neuroendocrine cancer type have been reported [9]. 
Prostate cancer stem cells (PCSC) have been shown in 
spheres from prostate cancer cell line DU-145 [10], from 
castration-resistant LNCaP cell line [11], and also from 
xenografts of prostate cancer specimen [12]. Spheres 
were obtained in cell cultures primarily with the aid of 
special culture media or Matrigel which are rich in growth 
factors. The characteristics of PCSC within the spheres, the 
mechanisms by which they renew and differentiate, as well 
as their androgen dependency have yet to be defined.
Epigenetic agents have been shown to be potentially 
effective treatments for prostate cancer [13, 14]. We have 
demonstrated that phenethyl isothiocyanate (PEITC) 
is an epigenetic agent with dual activity to inhibit DNA 
hypermethylation and histone deacetylation [15, 16]. In 
this study, LNCaP cell spheres were established after 
PEITC treatment. The sphere cells expressed cancer 
stem cell marker CD44 and had epigenomic alterations 
distinct from the parental LNCaP cells. The sphere cells 
can self-renew with androgen and also in androgen-
deprived condition. Furthermore, the sphere cells were 
capable of differentiating to neuroendocrine cells (NEC) 
when androgen was deprived. The NEC could reverse-
differentiate to spheres when androgen was replenished.
RESULTS
Establishment and structure of the prostate 
cancer spheres
LNCaP cells were exposed to PEITC at various 
concentrations and the development of spheres was 
investigated. PEITC at 4 μM was found to be optimal for 
mediating the formation of floating spheres after 4-7 days. 
There were no floating spheres in the control cultures of 
LNCaP cells without PEITC. The spheres were enriched 
with continued exposure to 3 μM PEITC for 8-12 days. 
With three different lots of LNCaP cell cultures examined, 
the number of spheres obtained were approximately 
0.46% (ranged from 0.18%-0.62%) of the starting LNCaP 
cells. Each floating sphere was initially composed of 
several cells, which grew larger in size to form the 
characteristic 3D-clusters (Figure 1A left, sphere). To 
demonstrate that the PEITC-induced spheres were indeed 
derived from the LNCaP cells, a separate LNCaP cell line 
expressing green fluorescent protein (GFP-LNCaP) was 
examined for sphere development. As shown in Figure 1A 
(center, GFP-sphere), the floating spheres with GFP 
fluorescence were reproducibly developed from the GFP-
LNCaP cell line following the same PEITC treatment 
protocol. This indicated that the spheres were formed 
de novo from the LNCaP cells, not due to contamination 
by other cells. Floating spheres could be maintained as 
long term culture in flasks with ultralow attachment, 
in RPMI-1640 medium and 10% regular FBS without 
PEITC, and they do not revert back to parental LNCaP 
cells. The spheres could form adherent culture in regular 
culture flasks, and had cells migrated outward from the 
spheres (Figure 1A right). The spheres were maintained 
in the long-term culture with morphology distinct from 
the LNCaP cell monolayer culture.
Furthermore, we have also examined the sphere 
formation properties of two other prostate cancer cell 
lines, PC-3 and DU-145. The sphere formation efficiencies 
and sizes of spheres were recorded (Supplementary 
Table S1). The quantity of spheres was approximately 
less than 0.05% of the starting PC-3 cells, approximately 
1/10th of the sphere formation efficiencies from LNCaP 
and GFP-LNCaP cell lines. Under similar conditions, no 
sphere formation was observed from DU-145. Thus, the 
sphere formation property appears to be intrinsic to the 
individual cell lines.
To examine the 3D-structure of the spheres, the 
spheres were prepared in paraffin blocks for H & E 
staining. Figure 1B shows a typical cross section of the 
LNCaP spheres (Figure 1B, sphere cross-section). Cells 
were shown to line up concentrically, with cell layers 
expanding circularly outward from the center. The outer 
cell layers were more tightly compacted than those in 
the interior. The sphere cells were relatively smaller 
than the parental LNCaP cells (Figure 1B, LNCaP), 
and displayed different morphology with oval shaped 
nuclei, high nuclear-cytoplasmic ratio, irregular nuclear 
contour and prominent nucleoli (Figure 1B). The LNCaP 
cells prepared identically had eccentric nuclei, irregular 
nuclear outlines and intermediate cytoplasm (Figure 1B 
left, LNCaP). The proliferation of the sphere cells was 
evaluated by immunostaining of Ki67, a marker of cell 
proliferation. Ki67 expression was found mainly in the 
periphery of the spheres, as shown in a typical staining 
(Figure 1B, Ki67 staining). The peripheral location of 
Ki67 expression and the concentric cell layers suggested 
a spherical growth pattern. To assess the self—renewal 
potential of the spheres, single cells from spheres were 
seeded with limiting dilution in medium with regular 
FBS. New spheres were regularly formed, which could be 
maintained for multiple generations and have been kept 
as long term cultures for more than two years. In these 
cultures the adherent spheres may detach and re-attach to 
the culture vessels during culture passage.
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Spheres grew slower in androgen-deficient 
medium
To determine the effect of androgen on the sphere 
cell growth, the spheres were cultured in medium with 
10% steroid hormone-depleted charcoal dextran-stripped 
FBS (CSF) which contains lower than castrate level 
of testosterone [17]. The sphere cultures in the CSF 
medium maintained good viability but grew slower than 
the spheres kept in the regular FBS medium. The spheres 
have been maintained in both types of media as long term 
cultures, and their proliferation was evaluated with cell 
cycle phase progression using flow cytometry. Figure 2A 
shows that the sphere culture in CSF medium (open bar) 
had significantly fewer replicating cells in S and G2M 
phases (19.2 ± 2.3%) than those spheres grown in the 
regular FBS medium (solid bar) (26.1± 1%)(P=0.022).The 
results indicated that the spheres could self-renew in the 
presence of androgen, but at a significantly slower rate in 
the absence of androgen.
Differentiation of sphere cells to 
neuroendocrine cells
We next examined the differentiation of sphere cells 
in the presence and absence of androgen. The monolayer 
cells spreading from adherent spheres underwent gradual 
morphological changes in the CSF medium, as compared 
to sphere cells cultured with regular FBS medium. 
The cells became elongated and displayed dendritic 
projections which were seen to bridge with other cells 
(Figure 2B). The cells had round nuclei, a high nuclear-
cytoplasmic ratio, and prominent nucleoli (Figure 2B). 
This morphology resembles the characteristics of neuroen-
docrine cells (NEC) [7, 8]. They were further examined 
for the presence of neuroendocrine cell markers by 
immunohistochemical staining. As summarized in Table 1, 
these cells were positive for serotonin, neuro-specific 
enolase, and pan-cytokeratin, the biochemical hallmarks 
of NECs. These markers were at background levels in the 
LNCaP cells and the spheres (Table 1).
Figure 1: Structure of LNCaP prostate cancer spheres. A. Representative bright-field images of LNCaP cell spheres cultured in 
RPMI-1640 medium with 10% FBS. From left to right are floating 3D-sphere, 400x magnifications; fluorescent image of a GFP-labeled 
LNCaP cell sphere, 400x magnifications; and an adherent sphere, 200x magnifications. B. The left is an image of H & E stained paraffin 
embedded LNCaP cells; the center is a cross section of a sphere, paraffin embedded and H& E stained; and the right is cross section of a sphere, 
paraffin embedded and immuno-stained for Ki67 expression. The dark spots are the Ki67 positive cells. Images are 400x magnifications.
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Since NEC differentiation was induced in medium 
with charcoal-stripped FBS (androgen-depleted), the 
involvement of androgen receptor (AR) in the differen-
tiation was investigated. AR expression in the NEC 
was at the background level, approximately 2.8 folds 
lower than that of the LNCaP cells, and approximately 
6.1 folds lower than that of sphere cells (Figure 2C). 
We also examined the expression of the transcription 
factor Sp1, which is known to mediate AR transcription 
[18, 19]. Sp1 mirrored the expression pattern of AR, 
with the LNCaP reduced approximately 5.7 folds than 
the spheres while the NEC expressed it only at the 
background level (Figure 2C). The level of PSA, which 
is a down-stream target gene of AR, also followed the 
Figure 2: Growth and differentiation of LNCaP-derived sphere cells. A. Cell cycle analysis of sphere cells. LNCaP sphere 
cultures maintained in RPMI-1640 medium with 10% regular FBS (solid column) or with10% charcoal-stripped FBS (CSF) (open column) 
were analyzed for cell cycle phase distribution by flow cytometry. Vertical bars are mean ± SD of 3 separate experiments. B. Neuroendocrine 
cells developed from adherent sphere cells in medium with 10% CSF on chamber slides, Pap stained, 400 x magnifications. C. Western 
blots showing the expression of androgen receptor (AR), Sp1, and PSA in LNCaP cells (maintained in regular FBS medium), spheres 
(maintained in regular FBS medium), and neuroendocrine cells (maintained in CSF medium). β-actin was used as a loading control. 
D. Immunohistochemical staining of AR in paraffin embedded preparations. From left to right are LNCaP cells, spheres (regular FBS 
medium), and neuroendocrine cells (CSF medium), 400x magnifications.
Table 1: Expression of neuroendocrine cell markers
Markers Staining intensity
LNCaP Spheres Neuroendocrine cells
Pancytokeratin +/− − +++
Neuro-specific enolase +/− − +++
Serotonin − − +
Definition of staining intensity: +/− : focally and weakly positive; − : negative; + : weakly positive; +++: strongly positive.
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expression pattern of AR, in that PSA in the LNCaP was 
approximately 7.5 folds lower than that of the sphere 
cells, and PSA in NEC was not detectable (Figure 2C). 
The reduced AR expression in the NEC was further 
verified by immunohistochemical staining of the cells 
prepared in paraffin block. Figure 2D shows that the 
NEC had a much reduced staining intensity of AR as 
compared to the LNCaP cells and the sphere cells. 
These results suggest that reduction of AR expression 
may be an important mechanism for the differentiation 
of spheres to NEC.
Reversible differentiation between spheres 
and neuroendocrine cells
When CSF culture medium was replaced with 
regular FBS medium for 7-14 days, the neuroendocrine 
cells gradually lost the dendritic morphology, and spheres 
reappeared on the monolayer, implying that androgen 
may propel neuroendocrine cells back to spheres. 
To further characterize the effect of androgen on the 
reformation of spheres from NEC, dihydrotestosterone 
(DHT) was added to the CSF culture medium. Addition 
of DHT from 1-80 nM induced sphere formation in a 
concentration-dependent manner. DHT at 10 nM was 
optimal, with spheres forming in 3-5 days. These spheres 
had significantly more replicating cells than the NEC, as 
indicated by Ki67 staining (Figure 3A). The spheres had 
approximately 28.3 ± 4.2% Ki67 positive cells, a major 
increase from 8.4 ± 2.1% of the NEC. The Ki67 level in 
the DHT-driven spheres was similar to that of the spheres 
grown in regular FBS medium (25.8 ± 3.6%), but more 
than those in the parental LNCaP cells (16.2 ±3.1%). 
AR expression in the reverted spheres was significantly 
increased, to approximately 5.5 folds more than that in 
the NEC (Figure 3B). The morphological and biochemical 
changes corroborated the androgen-dependent reversibility 
between the spheres and NEC. The plasticity of the sphere 
cells supports the notion that these spheres contain prostate 
cancer stem cells.
Distinct phenotype and invasive activity of 
spheres and neuroendocrine cells
Prostate cancer stem cells have been described to 
express surface marker CD44 [20, 21]. Flow cytometric 
analyses demonstrated that LNCaP cells had background 
level of CD44 staining, whereas approximately 28.1 ± 
16 % of the sphere cells grown in regular FBS medium 
were positive for CD44 (Figure 4A). The sphere cells 
maintained in CSF medium were approximately 35.2 ± 
12% positive for CD44, and the NEC approximately 42.2 
± 12% CD44–positive (Figure 4A). CD44 may thus be a 
sphere marker distinct from the parental LNCaP cells.
Anchorage-independent growth is one of the hallmarks 
of cell transformation and tumorigenic potential. To 
characterize whether the spheres and NEC have the capability 
of anchorage-independent growth, the cells were evaluated 
in soft-gel culture. The NEC and the sphere cells all formed 
significant number of colonies in soft agar gel, indicating that 
both cell types still retained tumorigenic potential. However, 
the number of colonies from the NEC (19.5 ± 5.9) was 
significantly lower than those from the spheres (46.5 ± 6.4) 
and the LNCaP cells (64.8 ± 7.7) (Figure 4B).
Figure 3: Reversible differentiation between LNCaP spheres and neuroendocrine cells. A. Immunohistochemical staining of 
Ki67 expression in LNCaP cells (maintained in regular FBS medium), spheres (regular FBS medium), neuroendocrine cells (CSF medium), 
and spheres reverse differentiated from the neuroendocrine cells (maintained in regular FBS medium). Columns and vertical bars represent 
means ± SD of 4 independent experiments. B. Western blots for androgen receptor (AR) expression in the neuroendocrine cells (CSF 
medium), spheres reverse differentiated from the neuroendocrine cells (maintained in regular FBS medium), and spheres (maintained in 
regular FBS medium). β-actin was used as a loading control.
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It is well known that carcinomas such as small 
cell lung cancer and small cell prostate cancer with 
neuroendocrine cell features metastasize early in the 
disease course. A Matrigel invasion chamber assay was 
used to examine the invasion capacity of the cells. In the 
presence of 10% regular FBS, the spheres had the lowest 
invasive activity with approximately 8.3 ± 1 invasive cells 
per membrane, as compared to the LNCaP cells, with 27.3 
±10.2 cells per membrane, and the NEC, with the highest 
activity at 37.6 ±12.3 cells per membrane (Figure 4C). 
The invasive activity of the NEC in the presence of 
charcoal-stripped FBS was approximately 32.6 ±1.2 
cells per membrane, similar to that when regular FBS 
was used as chemoattractant. This indicates that the 
invasive activity of the NEC is independent of androgen. 
This property is consistent with the cell nature of these 
neuroendocrine cells which developed in the absence of 
androgen. The tumor cell type rather than the androgen 
level may be the determining factor for chemotaxic 
migration and invasion.
Distinct epigenetic signatures of spheres
Epigenetic marks in the spheres were compared 
with those in the LNCaP cells. LNCaP cells and the 
great majority of clinical prostate tumors are known to 
have the π-class glutathione S-transferase gene (GSTP1) 
silenced due to promoter hypermethylation [22, 23]. The 
expression levels of GSTP1 in the spheres after PEITC 
exposure were clearly increased (approximately 6.7 
folds) in comparison to that of the untreated LNCaP cells 
(Figure 5A). Meanwhile, the expression level of DNA 
methyltransferase 1 (DNMT1), an enzyme responsible 
for DNA methylation, was significantly reduced in the 
Figure 4: Phenotype and invasive activity of sphere and neuroendocrine cells. A. CD44 expression. This figure shows the 
proportion of CD44 positive cells among LNCaP cells maintained in regular FBS medium, sphere cells maintained in regular FBS medium, 
sphere cells maintained in CSF medium, and neuroendocrine cells maintained in CSF medium, as determined by a flow cytometric method. 
Columns and vertical bars represent the means ± SD of four independent experiments. B. Soft-agar gel colony formation assay showing number 
of colonies per plate of LNCaP cells (prepared in regular FBS medium), spheres (prepared in regular FBS medium), and neuroendocrine 
cells (in CSF medium). Columns and vertical bars are means ± SD of 4 separate experiments. * indicates statistically significant difference in 
colony numbers between LNCaP and neuroendocrine cells, P<0.05. C. Matrigel migration assay. This figure shows the number of invasive 
cells per membrane of LNCaP cells (maintained in regular FBS medium), spheres (regular FBS medium), and neuroendocrine cells (CSF 
medium) from the Matrigel chamber invasion assay. Chemoattractant used in the lower chamber: solid bar (■) indicates regular FBS; open 
bar (▫) indicates charcoal-stripped FBS (CSF). Columns and vertical bars indicate the means ± SD of four separate experiments.
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spheres (approximately 5.7 folds), as compared to that of 
the parental LNCaP cells (Figure 5A). Figure 5A shows 
additionally that the level of acetylation of histone H3 
lysine position 4 (H3K4) was increased (approximately 
5 folds) in the spheres. Both the histone acetylation and 
DNMT1 changes were reported to be responsible for 
reactivating GSTP1 [15]. Activation of GSTP1 was further 
confirmed by in situ immunohistochemical staining of the 
sphere cells in paraffin blocks (Figure 5B). The sphere 
cells showed more intense staining. More sphere cells 
were positive for GSTP1 expression than LNCaP cells. 
The results indicated that the spheres had epigenomic 
signatures distinct from the parental LNCaP cells.
DISCUSSION
This study established prostate cancer cell spheres 
through treatment with an epigenetic modulator PEITC. 
The sphere cells can self-renew in media with and without 
androgen, and both can be maintained as cell lines in long-
term cultures. The phenotype of the LNCaP sphere cells is 
distinct from that of the parental LNCaP cells. The distinct 
characteristics of the sphere cells include the expression 
of CD44, higher expression levels of AR, Sp1, and PSA, 
as well as distinct epigenetic markers (Table 2). When 
androgen was depleted, the adherent spheres underwent 
differentiation to neuroendocrine cells. Like other types 
of tumor spheres, the LNCaP prostate cancer spheres have 
properties of cancer stem cells capable of self-renewal and 
differentiation [24–28]. Furthermore, the sphere formation 
property after PEITC treatment appears to be intrinsic to 
LNCaP cells, since sphere formation was reproducible in 
GFP-LNCaP cells, but no spheres from DU-145 cells and 
rare small spheres from PC-3 cells were observed under 
similar treatment. This may suggest that there may be 
unique epigenetic abnormalities in LNCaP cells.
Figure 5: Epigenetic marks of LNCaP sphere cells. A. Immunoblotting showing the expression levels of DNMT1 (DNA 
methytransferase 1), GSTP1 (π-class glutathione S-transferase), and acetylated histone H3 lysine 4 (H3K4) in LNCaP cells and sphere 
cells maintained in regular FBS medium. β-actin was used as a loading control. B. Immunohistochemical staining of GSTP1 on paraffin 
embedded preparations of LNCaP cells (left), and sphere cells (right) maintained in regular FBS medium.
Oncotarget26574www.impactjournals.com/oncotarget
The current finding of the prostate cancer 
sphere cells is in line with earlier reports of androgen-
independent prostate cancer stem cells [5, 6]. However, 
this is the first report of the dual capability of PCSC 
to self-renew with and without androgen. The results 
demonstrated that when the androgen quantity is 
decreased; the PCSC may reprogram to self-renew 
without androgen, and differentiate into progeny. The 
progeny could also reprogram and de-differentiate to 
PCSC when androgen is increased. Thus tumor cells may 
differentiate back and forth, capable of adapting to the 
microenvironment, growing according to the quantity of 
androgen.
The shuttle between PCSC and progeny differen-
tiation may shed light on the drug resistance to androgen 
deprivation therapy. When the androgen-sensitive tumor 
cells are eliminated by androgen deprivation therapy, 
PCSC may be spared since they can survive in androgen 
insufficient conditions. Under low androgen concentration, 
PCSCs differentiate to progenies with low AR expression 
and survive in an androgen-depleted condition, thus 
becoming refractory to androgen deprivation therapy. The 
neuroendocrine cells, after differentiating from spheres in 
androgen deficient condition, were demonstrated to revert 
back to spheres upon addition of DHT, in a concentration-
dependent manner. This indicates that the reversible 
process is androgen-dependent. However, the mechanism 
of de-differentiation from neuroendocrine cells to 
spheres remains unclear, as stem and progenitor cell 
differentiation is classically uni-directional. It has been 
shown that epithelial-to-mesenchymal transition (EMT) 
and vice versa can take place [29]. Whether the shuttling 
between spheres and neuroendocrine cells represents 
a new type of EMT (i.e., epithelial to neuroendocrine 
transition) remains to be determined. We hypothesize that 
androgenomic alterations govern the shuttling between 
sphere PCSC and neuroendocrine cells (Figure 6). In 
the absence of androgen, such as complete androgen 
blockade therapy or castration, androgenomic shutdown 
in the PCSC may lead to deceleration in proliferation 
and self-renewal, and initiate the differentiation process 
to progeny such as neuroendocrine cells (NEC). In the 
presence of androgen, the androgenome in the NEC may 
reprogram, allowing de-differentiation to spheres and 
the regaining of their properties. Albeit rare, prostate 
cancer with neuroendocrine cell features is known to 
have an aggressive nature with a poor prognosis [9]. 
The NEC in this study had demonstrated tumorigenic 
and invasive activities, as well as cellular and molecular 
features resembling NEC in clinical tumors. The current 
culture system may serve as a model for investigating this 
population of cancer cells.
In comparison to the LNCaP cells, the sphere cells 
displayed distinct epigenetic marks at the two major 
epigenetic transcriptional controls, i.e., covalent modi-
fication of histones and DNA methylation. They include 
enhancement of acetylation at histone H3K4, and activation 
of hypermethylated GSTP1 gene. Exposure to PEITC was 
previously demonstrated to reactivate the GSTP1 gene and 
its detoxification function, by inhibiting histone deacetylases 
Table 2: Comparison of the characteristics of LNCaP cells, spheres, and neuroendocrine cells
Markers and Properties Characteristics
LNCaP Spheres Neuroendocrine cells
Pancytokeratin +/− − +++
Neuro-specific enolase +/− − +++
Serotonin − − +
AR ++ +++ +
Sp1 +/− +++ −
PSA + +++ −
Ki67 ++ +++ +
CD44 <2% 46% 67%
Colony formation +++ ++ +
Invasive cells ++ + +++
DNMT1 +++ ++ +
GSTP1 + ++++ +++
Definitions: +/−: focally and weakly positive; −: negative; +: weakly positive; ++: moderately positive; >=+++: strongly 
positive.
Abbreviations: AR: androgen receptor; DNMT: DNA methyltransferase; GSTP: glutathione-S-transferase;
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and promoter hypermethylation of the GSTP1 gene [15, 16]. 
PEITC might also regulate the molecules involved in cellular 
adherence, which resulted in detachment of PEITC-treated 
cells from flasks, leading to sphere formation in culture 
supernatant. The detailed mechanism of PEITC effect on 
these cells remains to be further investigated. They include 
whether PEITC causes specific changes in cellular organelle 
structure [30], and gene expression for PCSC development 
[31], and whether PEITC affects telomere stability, as AR is 
associated with telomeres [32]. An investigation of signaling 
pathways mediated by PEITC relating to sphere development 
is currently being pursued.
This study described a simple, unique and 
reproducible methodology for establishment and 
maintenance of prostate cancer spheres. The sphere 
cells have properties of PCSCs since they can self-
renew and differentiate into neuroendocrine cells. 
Furthermore, the sphere cells can be manipulated to 
shuttle between spheres and neuroendocrine cells by 
adjusting androgen concentration. This has additionally 
described a method for establishment of a cell line 
that can shuttle between two distinct types of cells 
derived from the LNCaP cell line. This methodology 
might be applicable for establishment of spheres from 
other cell lines. More and more biomarkers are being 
discovered and validated for clinical diagnosis and 
therapeutic development [33–36]. Targeted therapy 
with small molecule inhibitors are translated rapidly to 
clinical applications [37–43]. The PCSC sphere cell line 
established herein can thus be used to screen for novel 
agents for prostate cancer therapy.
MATERIALS AND METHODS
Cell lines and reagents
Human prostate cancer LNCaP cell line at 
passage 21 and 31 were purchased from ATCC 
and characterized for fewer than 6 months before 
experimentation. An LNCaP cell line labeled with green 
fluorescent protein (GFP-LNCaP) was purchased from 
AntiCancer, Inc. (San Diego, California). LNCaP cells 
were maintained in RPMI-1640 medium supplemented 
with either 10% fetal bovine serum (regular FBS), or 
with 10% steroid hormone-depleted charcoal dextran-
stripped FBS (Hyclone) (CSF), and antibiotics. 
5-αdihydrotestosterone (DHT) was purchased from 
Sigma Chemical Company.
Figure 6: Hypothesis of a prostate cancer sphere model system. Androgen-dependent prostate cancer cells form spheres, with 
characteristics of prostate cancer stem cells (PCSC), due to epigenomic alterations mediated by an epigenetic modulator PEITC. This 
step is irreversible. PCSC retain tumorigenic potential and have dual proliferation capabilities allowing self-renewal in the presence and 
absence of androgen. In the absence of androgen (such as complete androgen blockade therapy/castration), PCSC cells are attenuated in 
proliferation and initiated differentiation process to neuroendocrine cells (NEC). The androgenome in the NEC cells are reprogramed in 
the presence of androgen, thereby the NEC cells can de-differentiate to spheres. Since LNCaP cells are epithelial in origin, this step may 
represent a new phenomenon, epithelial-to-neuroendorine and neuroendocrine-to-epithelial transition.
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Immunohistochemistry
Cultured cells were fixed in 10% neutral buffered 
formalin, and the centrifuged cells underwent routine 
paraffin-embedding as a cell block by the plasma thrombin 
method. Three to four micrometer sections of the paraffin-
embedded cell blocks were prepared for histology study 
and for immunohistochemistry. Monoclonal antibodies for 
the following proteins were used: pan cytokeratin (Ventana; 
AE1/AE3/PCK26); serotonin (Dako; 5HT-H209, 1:5 
dilutions); neuro-specific enolase (Ventana; MRQ-55); Ki67 
(Ventana; 30-9); androgen receptor (Ventana; SP107); π-class 
glutathione S-transferase (Santa Cruz biotechnology; A1513). 
Automated immunohistochemical system Ventana Bench 
Mark Ultra was used. Ventana ultra detection kit was used for 
staining and visualization. Positive controls included known 
pan cytokeratin, neuro-specific enolase, serotonin, Ki67, AR, 
and π-class glutathione S-transferase. Negative controls had 
primary antibody replaced by buffer and processed with the 
specimen slides. Immunohistochemistry was performed at the 
Department of Pathology, Westchester Medical Center, and 
immuostaining evaluated by an intensity scoring procedure. 
Cells were graded for the staining intensity as negative (-), 
focal and weak (±), weak to moderate (+), or strong (+++). 
Evaluations of specimen staining were performed by an 
independent pathologist without knowing the nature of the 
experiments.
LNCaP cell sphere development
LNCaP cells seeded at 1.5 x 105/ml of RPMI-1640 
medium with 10% regular FBS medium were exposed 
to 4 μM phenethyl isothiocyanate (PEITC). PEITC was 
supplemented every 2-3 days. PEITC was purchased from 
LKT Labs with 98% purity, which was prepared in phosphate 
buffered saline and DMSO [15, 16]. Cultures supplemented 
with vehicle control were used in every experiment. The non-
adherent cells in the supernatants, after exposure to PEITC 
for 4-10 days, were collected in regular culture flasks, which 
were continuously exposed to 3 μM PEITC for 8-12 days. 
The non-adherent spheres were collected by centrifugation, 
and cultured in flasks with ultralow attachment surface 
(Fisher Scientific). They were maintained in RPMI-1640 
medium with 10% FBS without PEITC for further studies. 
Adherent sphere culture was obtained by culturing the 
floating spheres in regular culture flasks. Individual spheres 
were isolated with limiting dilution in 96 well plates [44]. 
Dissociation of cells from spheres was aided with a non-
enzymatic cell dissociation solution (Sigma).The cells were 
further dispersed by repetitive pipetting through a glass 
Pasteur pipette, in combination with trypsin digestion and 
gently passing through 17 G, and 25 G needles.
Cell cycle analyses and immunoblotting
Cell cycle phase progression was measured by 
a BD FACS Calibur flow cytometer with the method 
described previously [45, 46]. The cells were fixed with 
80% ethanol at 4 oC, and incubated on ice before the 
DNA was stained with propidium iodide (50 μg/ml).The 
expression levels of cellular proteins were determined by 
quantitative Western blotting as previously described [47, 
48]. Images were recorded using chemilmager 5500 (Alpha 
Innotech). Antibodies were used to detect the following: 
C-terminal region of the androgen receptor (AR) (Santa 
Cruz Biotechnology;I299), Sp1 (Santa Cruz Biotechnology; 
E1304), prostate specific antigen (PSA) (Santa Cruz 
Biotechnology; C0414), DNA methytransferase 1 (DNMT1) 
(Santa Cruz Biotechnology; C0306), π-class glutathione 
S-transferase (GSTP1) (Santa Cruz Biotechnology; A1513), 
and β-actin (Sigma; 082M4781). The relative abundance of 
each protein obtained from the blot was calculated relative 
to the quantity of β-actin. Cells with surface CD44 were 
detected by a flow cytometric method with 10,000 live cell 
events analyzed per sample [49]. Cells were immunostained 
with a fluorescent conjugated monoclonal antibody against 
CD44 (BD Biosciences; clone 24345), and fixed with 1% 
paraformaldehyde. The proportion of the positively stained 
cells was determined against a background of cells stained 
with an isotype control.
Clonogenesis and cell invasion assay
Clonogenesis of cancer cells was assayed by a 
soft-gel semi-solid culture as previously described [49]. 
Essentially, 400-800 single cells were seeded in 1.5 ml 
soft-agar gel with RPMI-1640 medium with either 10% 
regular FBS or charcoal-stripped FBS per 35 x 10-mm 
culture dish. At least five duplicate dishes were used for 
each condition. Individual colonies with at least 30 cells 
were enumerated. Cell invasion assay was performed 
using a BD BioCoat Matrigel Invasion chamber (BD 
Biosciences) according to the procedure described. The 
upper chambers were seeded with 5 x 104 of LNCaP cells, 
dissociated cells from the spheres, or neuroendocrine cells 
which were scraped from the cultures. Chemoattractants 
were loaded in the lower chamber. These included 
10% FBS, or 10% charcoal–stripped FBS as indicated. 
Triplicate samples were assayed. Cells migrated into the 
lower chamber were fixed, stained with 1% toluidine blue 
and counted under light microscope.
Statistical analysis
All data were presented as mean ± SD from multiple 
independent experiments. The mean values of two groups 
of data were compared by the two-tailed Student’s t-test, 
with P<0.05 considered to be statistically significant.
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